NEW YORK, NY – July 12, 2016
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that data related to ANAVEX 2-73, the Company’s lead product candidate, will be presented in two poster presentations at the upcoming Alzheimer’s Association International Conference® 2016 (AAIC®) to be held from 24-28 July, 2016 in Toronto, Canada.
The poster presentations will feature data from the Company’s ongoing Phase 2a clinical study in patients with mild-to-moderate Alzheimer’s disease, highlighting ANAVEX 2-73 dose-response effect, Maximum Tolerated Dose (MTD) determination, as well as, 31 week safety, tolerability and exploratory efficacy assessment.
Presentation Details (#11011 and #12349):
Title: New Exploratory Alzheimer’s Drug ANAVEX 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients Date/Time: Sunday, July 24, 2016: 09:30 AM – 10:30 AM EDT Location: Metro Toronto Convention Centre, Hall D/E
Title: Safety and Efficacy 31 Week Data of ANAVEX 2-73 in a Phase 2a Study in Mild-Moderate Alzheimer’s Disease Patients Date/Time: Wednesday, July 27, 2016: 1:00 PM – 2:00 PM EDT Location: Metro Toronto Convention Centre, Hall D/E
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, is currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean safety profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
The Alzheimer’s Association International Conference® (AAIC®) is the world’s largest forum for the dementia research community. International investigators, clinicians and care providers gather annually to share the latest study results, theories and discoveries that bring the world closer to breakthroughs in dementia science.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: email@example.com
Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 firstname.lastname@example.org
Media: Jules Abraham JQA Partners, Inc. 917-885-7378 email@example.com